FDA accepts cefiderocol sNDA for serious gram-negative infections in children

The FDA has accepted Shionogi’s supplemental new drug application (sNDA) for cefiderocol (Fetroja) for use in pediatric patients with serious infections caused by susceptible gram-negative bacteria, according to a company announcement.¹ The company described the proposed pediatric use as addressing “serious infections caused by susceptible Gram-negative bacteria,” a population in which treatment options may be constrained by resistance patterns and limited pediatric labeling.¹

For clinicians, the regulatory milestone is notable because cefiderocol is already an FDA-approved agent for selected serious gram-negative infections in adults, including complicated urinary tract infections and hospital-acquired or ventilator-associated bacterial pneumonia caused by susceptible gram-negative organisms.² FDA acceptance of an sNDA begins the agency’s review process; it does not establish pediatric approval or define final labeling.

Cefiderocol is a siderophore cephalosporin designed to enter gram-negative bacteria by binding ferric iron and using bacterial iron transport systems, in addition to conventional porin-mediated entry.² This mechanism was developed to help overcome several resistance mechanisms seen in multidrug-resistant gram-negative pathogens, including reduced outer membrane permeability and some beta-lactamases.²

In adults, cefiderocol’s efficacy and safety have been evaluated in randomized trials across serious gram-negative infections. In the APEKS-NP phase 3 trial, cefiderocol was compared with high-dose, extended-infusion meropenem in adults with gram-negative nosocomial pneumonia. All-cause mortality at day 14 was similar between groups, supporting noninferiority for the trial’s primary end point.³

However, interpretation of cefiderocol’s role has been shaped by safety findings from the CREDIBLE-CR trial, which enrolled adults with serious carbapenem-resistant gram-negative infections. In that pathogen-focused trial, cefiderocol was compared with best available therapy and was associated with higher all-cause mortality in the cefiderocol group, particularly among patients with Acinetobacter infections.⁴ This finding is reflected in US prescribing information as a warning regarding increased all-cause mortality in patients with carbapenem-resistant gram-negative bacterial infections.²

That safety history is especially relevant for pediatric review. Children with serious gram-negative infections often have complex comorbidities, indwelling devices, prolonged hospital exposure, or intensive care needs. While pediatric patients may benefit from additional labeled options for resistant organisms, clinicians will need to understand whether the submitted data support age-appropriate dosing and whether safety signals observed in adults have been adequately evaluated or mitigated in children.

Current pediatric management of resistant gram-negative infections remains individualized and typically depends on infection site, local susceptibility data, source control, host factors, and consultation with infectious disease specialists. Cefiderocol, if approved for pediatric use, would not replace antimicrobial stewardship principles. Rather, its role would likely be determined by organism susceptibility, severity of illness, prior antibiotic exposure, and availability of alternative agents with pediatric dosing and safety experience.

Several questions remain unresolved from the accessible announcement. The FDA review timeline, proposed pediatric age range, specific infection syndromes, comparator regimen, and whether the application is supported primarily by pharmacokinetic bridging, clinical outcomes, or both were not reported.¹ The final regulatory decision and any accompanying label language will determine whether cefiderocol becomes an FDA-labeled option for pediatric patients and under what clinical circumstances.

References

1. BusinessWire. FDA Accepts Shionogi’s sNDA for Fetroja® (cefiderocol) for Use in Pediatric Patients with Serious Infections Caused by Susceptible Gram-negative Bacteria. July 16, 2026. Accessed July 16, 2026. https://www.businesswire.com/news/home/20260716553367/en/FDA-Accepts-Shionogis-sNDA-for-Fetroja-cefiderocol-for-Use-in-Pediatric-Patients-with-Serious-Infections-Caused-by-Susceptible-Gram-negative-Bacteria

2. US Food and Drug Administration. Fetroja (cefiderocol) prescribing information. Shionogi Inc.

3. Wunderink RG, Matsunaga Y, Ariyasu M, et al. Cefiderocol versus high-dose, extended-infusion meropenem for the treatment of gram-negative nosocomial pneumonia (APEKS-NP): a randomised, double-blind, phase 3, non-inferiority trial. Lancet Infect Dis. 2021;21(2):213-225. doi:10.1016/S1473-3099(20)30731-3

4. Bassetti M, Echols R, Matsunaga Y, et al. Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial. Lancet Infect Dis. 2021;21(2):226-240. doi:10.1016/S1473-3099(20)30796-9